Dimethyl sulfoxide (DMSO) is a solvent that is routinely used as a cryopreservative in allogous bone marrow and organ transplantation. We exposed C57Bl/6 mice of varying postnatal ages (P0-P30) to DMSO in order to study whether DMSO could produce apoptotic degeneration in the developing CNS. DMSO produced widespread apoptosis in the developing mouse brain at all ages tested. Damage was greatest at P7. Significant elevations above the background rate of apoptosis occurred at the lowest dose tested, 0.3 ml/kg. In an in vitro rat hippocampal culture preparation, DMSO produced neuronal loss at concentrations of 0.5% and 1.0%. The ability of DMSO to damage neurons in dissociated cultures indicates that the toxicity likely results from a direct cellular effect. Because children, who undergo bone marrow transplantation, are routinely exposed to DMSO at doses higher than 0.3 ml/kg, there is concern that DMSO might be producing similar damage in human children.
Introduction
Apoptosis, or programmed cell death, is the natural process whereby unneeded cells are eliminated via a sequence of genetically controlled steps (Lockshin and William, 1964) . In the brain there are two recognized periods during which cells undergo apoptosis. The first period of apoptosis occurs during the period of development when neural progenitor cells are actively proliferating (Miller et al., 2000) . During this period glucocorticoids produce apoptosis in the neural progenitor cells of the external granule cell layer of the cerebellum (Noguchi et al., 2008) . The second period occurs when post-mitotic neurons are integrating into functional circuits. Post-mitotic neurons that are unable to integrate successfully into developing CNS circuits and establish functional synapses are removed by apoptosis. Several classes of agents that suppress neuronal excitability can cause widespread apoptosis of neurons during this period of rapid synaptogenesis (Olney et al., 2002b) . These classes include antagonists of the NMDA subtype of glutamate receptor (Dribben et al., in press; Ikonomidou et al., 1999 Ikonomidou et al., , 2000 Scallet et al., 2004; Wang and Johnson, 2007) , GABAergic agents (Bittigau et al., 2002; Cattano et al., 2008; Ikonomidou et al., 2000; Johnson et al., 2008; Ma et al., 2007) and anticonvulsants (Bittigau et al., 2002; Glier et al., 2004; Ikonomidou et al., 2007) . While the period of vulnerability in rodents is entirely post-natal, encompassing the first two weeks of post-natal life, in humans, the corresponding period of vulnerability would extend from the last trimester of in utero life to the first several years of post-natal life (Dobbing and Sands, 1979) . Humans are commonly exposed to these classes of agents during the practice of medicine. Because exposure to these agents can produce long-term effects on cognition and behavior (Jevtovic-Todorovic et al., 2003; Noguchi et al., 2008; Wang et al., 2001; Wozniak et al., 2004; Yuede et al., 2005 Yuede et al., , 2006 this drug-induced apoptosis in the developing CNS is of growing concern. Recognition that non-human primates may also be sensitive to this drug-induced phenomenon (Farber et al., 2005; Slikker et al., 2007) has further heightened concern that human fetuses and infants, who are exposed to these agents in the practice of pediatric or obstetrical medicine or in the setting of maternal drug abuse, could be experiencing previously unrecognized neuronal injury.
While conducting several of the above studies we found evidence that dimethyl sulfoxide (DMSO), a commercially available solvent that is used extensively in industry and biological research, can also produce widespread apoptotic neurodegeneration in the developing mouse CNS. DMSO is considered a relatively safe solvent (Class 3) in doses up to 50 mg per day. It has been touted to have a wide variety of beneficial medical effects (Muir, 1996; Santos et al., 2003) and can be obtained over the Internet (e.g. www.dmso.org) and used without a 
